Pharmacogenetics of chemotherapy-induced nausea and vomiting

Shigekazu Sugino, Piotr K. Janicki

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.

Original languageEnglish (US)
Pages (from-to)149-160
Number of pages12
JournalPharmacogenomics
Volume16
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pharmacogenetics
Nausea
Vomiting
Antiemetics
Drug Therapy
Serotonin Agents
Serotonin Receptors
Biomarkers
Enzymes
Pharmaceutical Preparations
Genes
Proteins
Pharmacogenomic Testing

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

@article{6654d7af2ea347d08fda385bad0abfb4,
title = "Pharmacogenetics of chemotherapy-induced nausea and vomiting",
abstract = "Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.",
author = "Shigekazu Sugino and Janicki, {Piotr K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/pgs.14.168",
language = "English (US)",
volume = "16",
pages = "149--160",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "2",

}

Pharmacogenetics of chemotherapy-induced nausea and vomiting. / Sugino, Shigekazu; Janicki, Piotr K.

In: Pharmacogenomics, Vol. 16, No. 2, 01.01.2015, p. 149-160.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacogenetics of chemotherapy-induced nausea and vomiting

AU - Sugino, Shigekazu

AU - Janicki, Piotr K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.

AB - Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.

UR - http://www.scopus.com/inward/record.url?scp=84921645200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921645200&partnerID=8YFLogxK

U2 - 10.2217/pgs.14.168

DO - 10.2217/pgs.14.168

M3 - Review article

C2 - 25616101

AN - SCOPUS:84921645200

VL - 16

SP - 149

EP - 160

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 2

ER -